OptiNose develops nasal drug delivery technologies and novel combination drug/device therapies. The drug delivery technologies are based upon a unique and patent-protected principal Bi-Directional Delivery which allows drugs to be more efficiently delivered to the nasal cavity. By applying the Company's drug delivery technology, most of the dose is deposited beyond the nasal valve in the upper posterior two-thirds of the nasal cavity, unlike traditional devices.

The OptiNose delivery devices have high dose reproducibility and avoid drug deposition to the lungs. In summary, the technology fulfills the ideal requirements for nasal drug delivery. Clinical trials have shown the devices can provide a faster onset of action, greater effect with a lower dose and reduced side effects.

Type
Public
HQ
Oslo, NO
Founded
2000
Size (employees)
44 (est)+5%
OptiNose was founded in 2000 and is headquartered in Oslo, NO
Report incorrect company information

Key People/Management at OptiNose

Peter Miller

Peter Miller

CEO
Ramy Mahmoud

Ramy Mahmoud

President
Per Djupesland

Per Djupesland

CSO

OptiNose Office Locations

OptiNose has offices in Berkeley and Oslo
Oslo, NO (HQ)
Oslo Innovation Center
Berkeley, US
Berkeley House
Show all (2)
Report incorrect company information

OptiNose Financials and Metrics

OptiNose Financials

OptiNose's revenue was reported to be $47.50 m in FY, 2016 which is a 55782.4% increase from the previous period.
USD

Net income (Q3, 2017)

(13.1 m)

EBIT (Q3, 2017)

(13.2 m)

Market capitalization (23-May-2018)

911.8 m

Closing share price (23-May-2018)

24

Cash (30-Sep-2017)

49.4 m
OptiNose's current market capitalization is $911.8 m.
Annual
USDFY, 2015FY, 2016

Revenue

85 k47.5 m

Revenue growth, %

55782%

General and administrative expense

6 m6.9 m

R&D expense

22.2 m15.3 m
Quarterly
USDQ3, 2016Q3, 2017

General and administrative expense

1.8 m6.6 m

R&D expense

3.9 m6.6 m

Operating expense total

5.6 m13.2 m

EBIT

(5.6 m)(13.2 m)
Annual
USDFY, 2015FY, 2016

Cash

15.2 m36.8 m

Accounts Receivable

448 k384 k

Current Assets

15.8 m40.7 m

PP&E

191 k323 k
Quarterly
USDQ3, 2017

Cash

49.4 m

Accounts Receivable

231 k

Current Assets

50.3 m

PP&E

1.4 m
Annual
USDFY, 2015FY, 2016

Net Income

(28.3 m)22.6 m

Accounts Payable

450 k(130 k)

Cash From Operating Activities

(28.7 m)21.7 m

Purchases of PP&E

(80 k)(215 k)
Quarterly
USDQ3, 2016Q3, 2017

Net Income

28.2 m(29.4 m)

Inventories

(241 k)

Accounts Payable

(524 k)(574 k)

Cash From Operating Activities

27.7 m(21.9 m)
USDY, 2017

Financial Leverage

-0.3 x
Show all financial metrics

OptiNose Operating Metrics

Jun, 2017

Patents (US)

43

Patents Pending (US)

35

Trademarks (US)

3
Show all operating metrics
Report incorrect company information

OptiNose News and Updates

Report incorrect company information